Atrial fibrillation in 2010: An increasing morbidity and mortality burden;La fibrillation atriale en 2010: un poids croissant sur la morbidité et la mortalité cardiovasculaires

Annales de Cardiologie et d'Angeiologie

Volumn 59, Issue SUPPL. 1, 2010, Pages 514-513

  Davy, J M ^a   Roubille, F ^a   Tri Cung, T ^a   Massin, F ^a   Crausac, F ^a   Raczka, F ^a   Pasquie J L ^a  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Atrial fibrillation; Costs; Hospitalisation; Morbidity; Mortality

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT;

ARTICLE; BRAIN EMBOLISM; CARDIOVASCULAR RISK; COMORBIDITY; COMPLICATION; DRUG EFFICACY; EPIDEMIC; HEALTH CARE COST; HEALTH ECONOMICS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOSPITALIZATION; HUMAN; INCIDENCE; MORBIDITY; MORTALITY; PREVALENCE;

EID: 78650737733     PISSN: 00033928     EISSN: 17683181     Source Type: Journal    
DOI: 10.1016/S0003-3928(10)70002-0     Document Type: Article

References (48)

1. Tsang T., Gersh B.J. Atrial fibrillation: an old disease, a new epidemic. Am J Cardiol 2002, 113:432-435.
2. Stewart S., Hart C.L., Hole D.J., et al. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001, 86:516-521.
3. Ringborg A., Nieuwlaat R., Lindgren P., et al. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace 2008, 10:403-411.
4. Coyne K.S., Paramore C., Grandy S., et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 2006, 9:348-435.
5. Miyasaka Y., Barnes M.E., Gersh B.J., et al. Secular trends in incidence of atrial fibrillation in Olmstead County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006, 114:119-125.
6. Lloyd-Jones D.M., Wang T.J., Leip E.P., et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004, 110:1042-1046.
7. Camm J., Reiffel J.A. Defining endpoints in clinical trials on atrial fibrillation. European Heart Journal Supplements 2008, 10(Supplement H):H55-H78.
8. Kirchhof P., Auricchio A., Bax J., et al. Outcome parameters for trials in atrial fibrillation. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace 2007, 9:1006-1023.
9. Kannel W.B., Wolf P.A., Benjamin E.J., et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998, 82:2N-9N.
10. Krahn A.D., Manfreda J., Tate R.B., et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study. Am J Med 1995, 98:476-484.
11. Heeringa J., van der Kuip D.A., Hofman A., et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006, 27:949-953.
12. Furberg C.D., Psaty B.M., Manolio T.A., et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994, 74:236-241.
13. Stewart S., Hart C.L., Hole D.J., et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002, 113:359-364.
14. Levy S., Maarek M., Coumel P., et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. Circulation 1999, 99:3028-3035.
15. Nabauer M., Gerth A., Limbourg T., et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009, 11:423-434.
16. Langenberg M., Hellemons B.S., van Ree J.W., et al. Atrial fibrillation in elderly patients: prevalence and comorbidity in general practice. BMJ 1996, 313:1534.
17. Chugh S.S., Blackshear J.L., Shen W.K., et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001, 37:371-378.
18. Wattigney W.A., Mensah G.A., Croft J.B. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003, 108:711-716.
19. Tsang T.S., Petty G.W., Barnes M.E., et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester. Minnesota: changes over three decades. J Am Coll Cardiol 2003, 42:93-100.
20. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22:983-988.
21. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007, 69:546-554. The Stroke Risk in Atrial Fibrillation Working Group.
22. Marini C., De Santis F., Sacco S., et al. Contribution of Atrial Fibrillation to Incidence and Outcome of Ischemic Stroke Results From a Population-Based Study. Stroke 2005, 36:1115-1119.
23. Kilander L., Andren B., Nyman H., et al. Atrial fibrillation is an independent determinant of low cognitive function: a cross-sectional study in elderly men. Stroke 1998, 29:1816-1820.
24. Ott A., Breteler M.M., de Bruyne M.C., et al. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997, 28:316-321.
25. Savelieva I., Camm A.J. Atrial fibrillation and heart failure: natural history and pharmacological treatment. Europace 2004, 5. S5eS19.
26. Cleland J.G.F., Swedberg K., Follath F., et al. The EuroHeart failure survey programme - a survey on the quality of care among patients with heart failure in Europe.Part 1:patient characteristics and diagnosis. Eur Heart J 2003, 24:442-463.
27. Cohen-Solal A., Desnos M., Delahaye F., et al. for the myocardial and heart failure working group of the French Society of Cardiology, the National College of General Hospital Cardiologists and the French Geriatrics Society. A national survey of heart failure in French hospitals. Eur Heart J 2000, 21:763-769.
28. Nieuwlaat R., Capucci A., Camm A.J., et al. Atrial fibrillation management: a prospective survey in ESC Member Countries. The Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005, 26:2422-2434.
29. Wang T.J., Larson M.G., Levy D., et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003, 107:2920-2925.
30. Benjamin E.J., Wolf P.A., D'Agostino R.B., et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998, 98:946-952.
31. Asbach S., Olschewski M., Faber T.S., et al. Mortality in patients with atrial fibrillation has significantly decreased during the last three decades: 35 years of follow-up in 1627 pacemaker patients. Europace 2008, 10:391-394.
32. Frost L., Vestergaard P., Mosekilde L., et al. Trends in incidence and mortality in the hospital diagnosis of atrial fibrillation or flutter in Denmark, 1980-1999. Int J Cardiol 2005, 103:78-84.
33. Jouven X., Desnos M., Guerot C., et al. Idiopathic atrial fibrillation as a risk factor for mortality. The Paris Prospective Study I. Eur Heart J 1999, 20:896-899.
34. Jahangir A., Lee V., Friedman P.A. Long-Term Progression and Outcomes With Aging in Patients With Lone Atrial Fibrillation A 30- Year Follow-Up Study. Circulation 2007, 115:3050-3056.
35. Wyse D.G., Slee A., Epstein A.E., et al. Alternative endpoints for mortality in studies of patients with atrial fibrillation: the AFFIRM study experience. Heart Rhythm 2004, 1:531-537.
36. Lumer G.B., Roy D., Talajic M., et al. Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial. Eur Heart J 2002, 23:1050-1056.
37. Hagens V.E., Vermeulen K.M., TenVergert E.M., et al. Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation-results from the RAte Control versus Electrical cardioversion (RACE) study. Eur Heart J 2004, 25:1542-1549.
38. Marshall D.A., Levy A.R., Vidaillet H., et al. Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Ann Intern Med 2004, 141:653-661.
39. Botkin S.B., Dhanekula L.S., Olshansky B. Outpatient cardioversion of atrial arrhythmias: Efficacy, safety, and costs. AmHeart J 2003, 145:233-238.
40. Grönefeld G., Ehrlich J.R., Hohnloser S.H. Comparison of outpatient vs inpatient direct current cardioversion of atrial fibrillation: safety, efficacy and cost savings. Eur Heart J 2003, 5:H19-H24.
41. Zimetbaum P., Reynolds M.R., Ho K.K.L., et al. Impact of a practice guideline for patients with atrial fibrillation on medical resource utilization and costs. Am J Cardiol 2003, 92:677-681.
42. Weerasooriya R., Jais P., Le Heuzey J.Y., et al. Cost analysis of catheter ablation for paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 2003, 26:292-294.
43. Khaykin Y., Morillo C.A., Skanes A.C., et al. Cost comparison of catheter ablation and medical therapy in atrial fibrillation. J Cardiovasc Electrophysiol 2007, 18:907-913.
44. Andrikopoulos G., Tzeis S., Maniadakis N., et al. Cost-effectiveness of atrial fibrillation catheter ablation. Europace 2009, 11:147-151.
45. McKenna C., Palmer S., Rodgers M., et al. Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the United Kingdom. Heart 2009, 95:542-549.
46. Le Heuzey J.Y., Paziaud O., Piot O., et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J 2004, 147:121-126.
47. Reynolds M.R., Essebag V., Zimetbaum P., et al. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol 2007, 18:628-633.
48. McBride D., Mattenklotz A.M., Willich S.N., et al. The Costs of Care in Atrial Fibrillation and the Effect of Treatment Modalities in Germany. Value Health 2009, 12:293-301.